Grants and Contributions:
Title:
Project Peregrine: Building and Accelerating Antibody Drug Development Capabilities in Canada
Agreement Number:
819720
Agreement Value:
$225,000,000.00
Agreement Date:
Mar 18, 2022 - Mar 31, 2030
Description:
This project builds capabilities for therapeutic antibody development, fortifies early-phase clinical research infrastructure, advances biotech IP for the health and economic benefit of Canadians and enables rapid response to future pandemics.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:
The investment will allow the company to increase its capabilities in the drug development value chain to advance a portfolio of high value antibody drug targets through pre-clinical and phase 1 clinical work.
Location:
Vancouver, British Columbia, CA V5Y0A1
Reference Number:
033-2023-2024-Q1-819720
Agreement Type:
Other transfer payment
Report Type:
Grants and Contributions
Recipient Business Number:
838509446
Recipient Type:
For-profit organization
Additional Information:
This is a partially repayable contribution
Recipient's Operating Name:
AbCellera
Recipient's Legal Name:
AbCellera Biologics Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
SIF Stream3- Attraction
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
NAICS Code:
541710